Axon Enterprise (NASDAQ:AXON) Price Target Raised to $725.00 at JMP Securities

Axon Enterprise (NASDAQ:AXON) had its target price boosted by JMP Securities from $610.00 to $725.00 in a research note issued to investors on Tuesday morning,Benzinga reports. JMP Securities currently has a market outperform rating on the biotechnology company’s stock.

Several other equities analysts also recently issued reports on AXON. Northland Securities raised their price target on shares of Axon Enterprise from $365.00 to $550.00 and gave the company an “outperform” rating in a research note on Monday, November 11th. TD Cowen initiated coverage on Axon Enterprise in a report on Wednesday, January 8th. They set a “buy” rating and a $700.00 target price on the stock. Morgan Stanley raised Axon Enterprise from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $500.00 to $700.00 in a research note on Tuesday, December 3rd. Robert W. Baird lifted their price objective on Axon Enterprise from $600.00 to $800.00 and gave the stock an “outperform” rating in a research note on Friday, December 6th. Finally, The Goldman Sachs Group increased their target price on shares of Axon Enterprise from $500.00 to $700.00 and gave the company a “buy” rating in a research report on Monday, January 27th. One equities research analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $542.15.

Axon Enterprise Stock Performance

Axon Enterprise stock opened at $662.91 on Tuesday. The business has a 50 day moving average of $621.03 and a 200-day moving average of $488.66. The company has a market capitalization of $50.55 billion, a P/E ratio of 171.30, a P/E/G ratio of 6.54 and a beta of 1.05. Axon Enterprise has a 1 year low of $252.20 and a 1 year high of $698.67. The company has a debt-to-equity ratio of 0.32, a current ratio of 2.96 and a quick ratio of 2.63.

Insider Activity

In related news, President Joshua Isner sold 20,000 shares of Axon Enterprise stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $606.15, for a total value of $12,123,000.00. Following the completion of the sale, the president now owns 208,166 shares of the company’s stock, valued at approximately $126,179,820.90. This trade represents a 8.77 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Jeffrey C. Kunins sold 21,834 shares of the company’s stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $593.88, for a total transaction of $12,966,775.92. Following the transaction, the insider now owns 154,394 shares in the company, valued at approximately $91,691,508.72. The trade was a 12.39 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 50,545 shares of company stock worth $30,721,337 in the last three months. Company insiders own 5.70% of the company’s stock.

Institutional Trading of Axon Enterprise

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Public Sector Pension Investment Board boosted its position in shares of Axon Enterprise by 19.2% during the third quarter. Public Sector Pension Investment Board now owns 3,104 shares of the biotechnology company’s stock valued at $1,240,000 after buying an additional 500 shares during the last quarter. CIBC Asset Management Inc grew its stake in shares of Axon Enterprise by 9.2% in the 3rd quarter. CIBC Asset Management Inc now owns 10,578 shares of the biotechnology company’s stock worth $4,227,000 after acquiring an additional 895 shares in the last quarter. Foundations Investment Advisors LLC bought a new position in shares of Axon Enterprise during the third quarter valued at about $221,000. Sequoia Financial Advisors LLC boosted its holdings in Axon Enterprise by 4.9% during the third quarter. Sequoia Financial Advisors LLC now owns 1,727 shares of the biotechnology company’s stock worth $690,000 after purchasing an additional 81 shares during the last quarter. Finally, Axxcess Wealth Management LLC bought a new stake in Axon Enterprise in the 3rd quarter worth about $814,000. 79.08% of the stock is owned by institutional investors.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.